1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
Real-time Estimate Cboe BZX  -  17:18 06/07/2022 BST
157.98 USD   -1.89%
03:40pCanaccord Genuity Assumes BioNTech at Buy with $192 Price Target
MT
11:17aMARKETSCREENER'S WORLD PRESS REVIEW : July 6, 2022
11:04aBIONTECH : Statement on Patent Infringement Lawsuit in Germany - Form 6-K
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
141.98(c) 149.1(c) 157.5(c) 161.03(c) 156.87 Last
1 054 370 2 495 583 1 335 180 1 651 658 433 276 Volume
+1.54% +5.01% +5.63% +2.24% -2.58% Change
More quotes
Estimated financial data (e)
Sales 2022 16 835 M 17 247 M 14 487 M
Net income 2022 9 580 M 9 814 M 8 244 M
Net cash position 2022 16 333 M 16 733 M 14 055 M
P/E ratio 2022 4,31x
Yield 2022 -
Sales 2023 9 722 M 9 960 M 8 366 M
Net income 2023 4 926 M 5 047 M 4 239 M
Net cash position 2023 25 147 M 25 762 M 21 639 M
P/E ratio 2023 8,49x
Yield 2023 -
Capitalization 38 198 M 39 133 M 32 870 M
EV / Sales 2022 1,30x
EV / Sales 2023 1,34x
Nbr of Employees 3 082
Free-Float 87,3%
More Financials
Company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer... 
More about the company
Ratings of BioNTech SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about BIONTECH SE
03:40pCanaccord Genuity Assumes BioNTech at Buy with $192 Price Target
MT
11:17aMARKETSCREENER'S WORLD PRESS REVIEW : July 6, 2022
11:04aBIONTECH : Statement on Patent Infringement Lawsuit in Germany - Form 6-K
PU
07/05Germany's CureVac files suit against vaccine rival BioNTech
AQ
07/05BioNTech Says Will 'Vigorously' Defend Patent Infringement Allegations
MT
07/05BioNTech Says 'Work is Original' Amid CureVac Lawsuit On mRNA-Related Patents Infringem..
MT
07/05BIONTECH : Statement on Patent Infringement Lawsuit in Germany
PU
07/05European ADRs Plunge in Tuesday Trading
MT
07/05Switzerland to Order 3.5 Million Doses of Pfizer-BioNTech, Moderna COVID-19 Jabs for FY..
MT
07/05SECTOR UPDATE : Health Care Stocks Decline Premarket Tuesday
MT
07/05CureVac Sues BioNTech in Germany for Infringement of mRNA-Related Patents
MT
07/05CureVac Sues BioNTech for Alleged Infringement of Some COVID-19 Vaccine Patents
MT
07/05CureVac Files Patent Infringement Lawsuit Against BioNTech Over Covid Vaccine
DJ
07/04African Union Commission Chairperson Statement At the Vaccine Equity for Africa Groundb..
AQ
07/01European ADRs Fall Sharply in Friday Trading
MT
More news
News in other languages on BIONTECH SE
11:12aBIONTECH : la pharma attaquée en justice par CureVac
10:49aBIONTECH, UNILEVER, JPMORGAN EN JUST : Planète Bourse du 6 juillet
08:03aL'équation se complique à nouveau
07:35aEN DIRECT DES MARCHES : Schneider, Alstom, EDF, GTT, ASML, BYD, Uniper, Albioma, Holcim...
07/05MÄRKTE USA/Turbulenter Wochenstart - Ölpreise brechen ein
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 157,18 €
Average target price 227,67 €
Spread / Average Target 44,8%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Ízlem TŘreci Chief Medical Officer
Sierk P÷tting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-37.54%39 133
GILEAD SCIENCES, INC.-14.14%78 194
VERTEX PHARMACEUTICALS31.59%73 908
REGENERON PHARMACEUTICALS, INC.-5.54%64 277
WUXI APPTEC CO., LTD.-4.30%49 127
GENMAB A/S-8.48%21 675